Supplementary data crisaborole/dupi

Description

Supplementary Table I. Reasons for exclusion of studies. Supplementary Table II. Non-English language studies included Supplementary Table III. Conclusions of crisaborole commentorials Supplementary Table IV. Dupilumab extracted data Supplementary Table V. Crisaborole extracted data

Categories

Licence